Other Issues

Browse Other Issues Content

Since the Final Rule was published in 1995, FDA has received six Citizen Petitions (CPs) requesting the addition of alternatives to the animal caries test to the Anticaries Monograph.

CHPA has concerns with granting unilateral authority to temporarily schedule substance restrictions, without legislative oversight or consent

Safe use of acetaminophen is a top priority for manufacturers of OTC medicines. Manufacturers work closely with FDA, healthcare provider groups, pharmacist groups, and consumer health advocates to drive safe and responsible use of acetaminophen.

Industry Self-Regulation for Dietary Supplements

This document serves as a voluntary guideline to assist manufacturers of dietary supplements with compliance with the dietary supplement current good manufacturing practice (cGMP) requirements of the US FDA 21 CFR §111.

Learn about the uses, safety, and regulation of homeopathic medicines in the U.S.

FDA Announcement of a proposed safety-based Administrative Order to update the pregnancy warning labeling for NSAID-containing drug products.

CHPA generally supports prohibitions on animal testing while allowing exemptions in select research areas deemed critical to substantiating human health and safety based on federal or state regulator evaluations.

The success of healthcare vending indicates many consumers welcome the affordability and around-the-clock availability these machines provide. As the trend accelerates, people across socioeconomic backgrounds are empowered to conveniently tend to their healthcare needs.

Informed Consumer Decision Making

The following information on botanical ingredients should be included in either a bulk botanical raw material specification sheet (for business-to-business transactions) or finished product labeling (when selling directly to consumers).

Filter Results